Delavirdine: Clinical Trials

18 completed, 2 terminated, 1 withdrawn. 8 Phase 2, 7 Not applicable, 5 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	8	Completed 6, Terminated 1, Withdrawn 1
Not applicable	7	Completed 6, Terminated 1
Phase 3	5	Completed 5
Phase 1	1	Completed 1

Follow Delavirdine: new trials by email Literature Review of Delavirdine trials Research Report on Delavirdine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections	Phase 2 / Phase 3	Completed	University of California, San Diego	59	2007-03-01	2014-04-23
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients Rescriptor - HIV-1 Infection		Completed	Pfizer	3	2003-12-01	2010-07-05
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir Indinavir sulfate, Ritonavir, Delavirdine mesylate - HIV Infections	Not applicable	Terminated	Agouron Pharmaceuticals	60	2000-08-01	2005-06-24
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir Tipranavir (TPV), Ritonavir (RTV), Delavirdine (DLV) - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	18	1999-03-01	2014-09-25
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3 Delavirdine mesylate, Lamivudine, Zidovudine - HIV Infections	Phase 3	Completed	Pharmacia and Upjohn	1250		2005-06-24
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy Delavirdine mesylate, Zidovudine, Didanosine - HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	471		2021-11-04
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors Emivirine, Hydroxyurea, Delavirdine mesylate - HIV Infections	Phase 2	Terminated	Bristol-Myers Squibb	25		2008-08-14
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies Delavirdine mesylate - HIV Infections	Phase 2	Completed	Pharmacia and Upjohn	24		2005-06-24
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients Indinavir sulfate, Delavirdine mesylate, Lamivudine - HIV Infections	Not applicable	Completed	Pharmacia and Upjohn	160		2005-06-24
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3 Delavirdine mesylate, Didanosine - HIV Infections	Phase 3	Completed	Pharmacia and Upjohn			2005-06-24
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients Nelfinavir mesylate, Delavirdine mesylate, Stavudine - HIV Infections	Not applicable	Completed	Pharmacia and Upjohn	160		2005-06-24
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients Indinavir sulfate, Delavirdine mesylate, Zidovudine - HIV Infections	Not applicable	Completed	Pharmacia and Upjohn	32		2005-06-24
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir Ritonavir, Nelfinavir mesylate, Levocarnitine - HIV Infections	Not applicable	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	300		2021-11-04
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S) Delavirdine mesylate, Zidovudine, Didanosine - HIV Infections	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	120		2021-11-04
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir - HIV Infections	Phase 2	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)			2015-03-09
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine Delavirdine mesylate, Zidovudine - HIV Infections	Not applicable	Completed	Pharmacia and Upjohn			2005-06-24
A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients Ritonavir, Nelfinavir mesylate, Saquinavir - HIV Infections	Phase 3	Completed	Hoffmann-La Roche	375		2005-06-24
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients Ritonavir, Nelfinavir mesylate, Saquinavir - HIV Infections	Phase 3	Completed	Hoffmann-La Roche	825		2005-06-24
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients Indinavir sulfate, Delavirdine mesylate, Lamivudine - HIV Infections	Not applicable	Completed	Pharmacia and Upjohn	45		2005-06-24
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects Indinavir sulfate, Delavirdine mesylate, Lamivudine - HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	300		2013-07-29

Showing 20 of 21. Sign in to see all of them.

Conditions studied

HIV Infections (20)  ·  AIDS-Related Complex (4)  ·  Acquired Immunodeficiency Syndrome (4)  ·  AIDS Dementia Complex (1)  ·  Cognitive Dysfunction (1)  ·  Hypersensitivity, Delayed (1)

Sponsors

Pharmacia and Upjohn (8)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (6)  ·  Hoffmann-La Roche (2)  ·  Agouron Pharmaceuticals (1)  ·  Boehringer Ingelheim (1)  ·  Bristol-Myers Squibb (1)  ·  Pfizer (1)  ·  University of California, San Diego (1)

Countries

United States (19)  ·  Puerto Rico (6)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Fischl M (2)  ·  Bartlett J (1)  ·  D Katzenstein (1)  ·  Fischl MA (1)  ·  Friedland G (1)  ·  Harold Kessler (1)  ·  Hernan Valdez (1)  ·  Johnson V (1)  ·  Kimberly Smith (1)  ·  Kuritzkes D (1)  ·  Michael Lederman (1)  ·  Para M (1)  ·  Pollard R (1)  ·  R Gulick (1)

Results publications

PMID 11023461, PMID 12195349, PMID 15031785, PMID 15295692, PMID 16249704, PMID 17507321, PMID 24352352

NIH funding

R01MH058076 (1)